Biomarker-Driven Lung Cancer Care: Application of New Standards and the Latest Research

Are you testing for all available biomarkers for NSCLC? Make sure you are up to date!

Join us live in Chicago or online for this 2-hour interactive symposium as our experts in NSCLC discuss current and emerging data on biomarker testing and targeted therapy for the treatment of patients with NSCLC. You will be able to ask questions to the experts whether you join us in-person or virtually!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

Agenda

Welcome and Introduction

Importance of Molecular Testing in NSCLC and Practical Considerations for Clinical Practice

Treatment Options for The Most Common Targetable Biomarkers for Advanced NSCLC: EGFR, KRAS, and HER2

Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, TRK, and MET

Audience Question and Answer Session and Final Thoughts

Events

Date / Time
Event Details

Faculty

Faculty
Todd M. Bauer, MD

Senior Investigator, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Faculty
Narjust Florez, MD

Associate Director of the Cancer Care Equity Program
Thoracic Oncologist
The Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Boston, Massachusetts

Faculty
Karen L. Reckamp, MD, MS

Professor of Medicine
Director
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimally assess biomarkers and then effectively and safely integrate novels agents into their practice for patients with NSCLC.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized treatment strategies for patients with advanced NSCLC based on available evidence, expert recommendations, and tumor molecular profile
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, along with racial, age, and socioeconomic disparities
  • Assess all patients with advanced NSCLC for appropriate currently available biomarkers to guide treatment selection and clinical trial eligibility
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.